Protagenic Therapeutics Inc. has announced an update regarding its business combination with Phytanix Bio Inc. The company recently generated $3.1 million in cash through warrant exchanges and exercises, which will support its operational needs and progress its peptide-based drug candidates targeting stress-related and central-nervous-system disorders. This merger brings together a total of six complementary drug programs, covering areas such as stress disorders, epilepsy, and obesity, under one entity. The collaboration aims to enhance the development of innovative treatments using both peptides and cannabinoid-like molecules.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。